Top Ten most popular articles on Pharmafile.com this week

pharmafile | August 18, 2017 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing life sciences, medicine, pharma, pharmaceutical, top ten 

A lot has happened in the world this week, but the pharma industry still found itself on the frontlines of world events as MSD CEO Kenneth Frazier stood up to Trump in the wake of the Charlottlesville violence and resigned from the American Manufacturing Council, sparking an exodus of executives which only days later led to President scrapping the group entirely in an attempt to save some shred of his plummeting reputation. The effects of the revelation could be strongly felt in the future, as industry confidence in Trump has now all but evaporated and his ‘America first’ manufacturing policy is left floundering.

Elsewhere, BMS is dealing with the fallout of yet another disappointment for its once-heralded ‘wonder drug’ Opdivo, as the drug failed to meet its targets as a combination treatment in a new trial. Also, don’t miss our piece authored by Paul Workman, Chief Executive and President of the Institute of Cancer Research, on the rising cost of cancer treatments – our most popular article this week.

Check out the week’s ten most popular articles on Pharmafile.com now!

10. NICE knocks back advanced kidney cancer drug duo

NICE has dished out a double judgement turning down Eisai’s Kisplyx (lenvatinib) and Eusa Pharma’s Fotivda (tivozanib) for advanced renal cell carcinoma.

9. ‘Hugely disturbing’ rise in UK children with type 2 diabetes, report finds

A report from the Royal College of Paediatrics and Child Health (RCPCH) has highlighted a “hugely disturbing” rise in cases of type 2 diabetes in children and teenagers in the UK.

8. Independent research may change the immunotherapy game

Two studies published in Nature may be able to explain some of the reasons for this and potentially offer a way to boost the success rates of the PD-L1 inhibitors.

7. Japanese telecom giant injects $1.1bn into Swiss biotech in largest-ever investment of its kind

In possibly the biggest single biotech investment ever made, Swiss biotech firm Roivant has received a $1.1 billion cash injection thanks to an investment from Japanese telecom giant SoftBank.

6. Novo diabetes drug outperforms Lilly rival at Phase 3

Novo Nordisk has revealed that its diabetes drug semaglutide managed to outperform Eli Lilly’s own treatment dulaglutide (Trulicity) in controlling glucose levels and promoting weight loss in patients with the type 2 form of the disease when combined with metformin.

5. MSD CEO sparks exodus from Trump’s manufacturing council over Charlottesville violence

MSD Chairman and Chief Executive Officer Kenneth Frazier (pictured) has announced that he is to resign from Donald Trump’s American Manufacturing Council in the wake of the violent clashes in Charlottesville, Virginia.

4. Continuous manufacturing: Upgrading the supply chain to meet rising demand

Pharmaceutical production has long been the object of scrutiny to ensure the highest levels of quality and safety are maintained. However, a new functional model is gaining momentum, promising greater speed and efficiency. But is it a one-size-fits-all solution? Matt Fellows investigates

3. BMS left red-faced as Opdivo+Yervoy fails to beat rival Pfizer drug in kidney cancer

Bristol-Myers Squibb’s combination of Opdivo and Yervoy failed to show any statistically significant benefits in progression-free survival versus Pfizer’s Sutent in advanced kidney cancer.

2. Gilead set to open $250m, 23-acre campus

Gilead is set for the grand unveiling of its new facility in La Verne, Southern California, after several years of work. The facility, once it is running at full capacity, is it to create jobs for 500 workers.

1. Ending the era of $100,000 cancer drugs

Paul Workman, Chief Executive and President of the Institute of Cancer Research, examines the spiralling cost of cancer treatments and what can be done to bring them down to a manageable level whilst ensuring patients receive the best treatment.

Related Content

Pfizer sign

Delayed Pfizer vaccine dose gives 3.5 times more immunity, study shows

The Pfizer-BioNTech COVID-19 vaccine is around three and a half times more effective when dosed …

Amgen flag

AstraZeneca and Amgen asthma drug shows positive results in Phase III trial

AstraZeneca and Amgen’s new tezepelumab drug for the treatment of severe asthma has shown superiority …

India report record number of COVID deaths as bodies drift down Ganges

India yesterday reported the country’s highest COVID-19 death total for a single day, with 4,205 …

Latest content